- Home
- LH vs ILMN Comparison
LH vs ILMN Comparison
Compare LH & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LH | ILMN |
|---|---|---|
| Founded | 1971 | 1998 |
| Country | United States | United States |
| Employees | 70000 | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9B | 20.4B |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | LH | ILMN |
|---|---|---|
| Price | $264.29 | $126.52 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 17 |
| Target Price | ★ $308.30 | $124.24 |
| AVG Volume (30 Days) | 508.2K | ★ 1.7M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | 18.33 | ★ 170.87 |
| EPS | ★ 10.46 | 5.45 |
| Revenue | ★ $13,951,700,000.00 | $4,343,000,000.00 |
| Revenue This Year | $8.36 | $6.52 |
| Revenue Next Year | $4.73 | $5.49 |
| P/E Ratio | $25.43 | ★ $22.49 |
| Revenue Growth | ★ 7.25 | N/A |
| 52 Week Low | $209.38 | $68.70 |
| 52 Week High | $293.72 | $155.53 |
Technical Indicators
Market Signals| Indicator | LH | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 52.68 |
| Support Level | $258.99 | $124.27 |
| Resistance Level | $268.11 | $135.68 |
| Average True Range (ATR) | 5.78 | 4.09 |
| MACD | -1.73 | 0.48 |
| Stochastic Oscillator | 5.16 | 63.67 |
Price Performance
Historical ComparisonAbout LH Laboratory Corporation of America Holdings
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.